(RTTNews) - Lantheus Holdings (LNTH) announced acquisition of Meilleur Technologies, which includes NAV-4694, expanding the company's Alzheimer's disease pipeline. Through the acquisition, Lantheus has the worldwide exclusive rights to ß amyloid PET imaging agent, NAV-4694, which is in Phase 3 development. The company said the acquisition of this asset complements its next generation F18-labeled PET imaging agent candidate, MK-6240.
Lantheus will provide an upfront payment as well as potential additional development and commercial milestone payments. Also, Lantheus will make royalty payments for research revenue and commercial sales.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
